Sacituzumab govitecan plus pembrolizumab fails to meet primary endpoints in first‑line PD‑L1‑high metastatic NSCLC, dealing a setback to the ADC‑immunotherapy combo approach
Executive summary: The Phase 3 EVOKE-03/KEYNOTE-D46 trial of sacituzumab govitecan combined with pembrolizumab did not achieve statistically significant progression‑free or overall survival benefits despite showing numeric PFS and response rate improvements. The result undermines the therapeutic rationale for pairing this ADC with pembrolizumab in PD‑L1‑high metastatic NSCLC, potentially affecting development timelines and market expectations for the drugs.
Who is involved: Gilead (developer of sacituzumab govitecan), Merck (maker of pembrolizumab), trial investigators, and patients with PD‑L1‑high metastatic NSCLC.
Likely next: Companies may analyze subgroup data, consider alternative combinations or dosing regimens, and decide whether to pursue further clinical development or redirect resources to other oncology assets.
The Phase 3 EVOKE-03/KEYNOTE-D46 study reported numerical improvements in progression‑free survival and response rates but did not achieve statistical significance for either PFS or overall survival. This outcome suggests that the combination may not offer a meaningful advantage over existing standards in this patient population. Consequently, Gilead and Merck may need to reassess the clinical development path for this pairing in NSCLC.
What's next — scenarios
Broad ADC-IO Combination Skepticism (50%)
Pharma companies will immediately deprioritize upcoming Phase 3 trials combining TROP2 ADCs with checkpoint inhibitors in first-line NSCLC, reallocating capital to monotherapy or novel bispecific approaches.
- Gilead and Merck announce termination or significant downsizing of the EVOKE clinical program in lung cancer
- Competitors alter trial designs for competing TROP2 ADC plus IO combinations within the next 60 days
Subgroup Pivot Strategy (35%)
Gilead and Merck will attempt to salvage the asset by mining subgroup data (e.g., specific PD-L1 expression tiers or biomarker subsets) to justify narrower, biomarker-driven Phase 3 follow-up studies.
- Presentation of detailed sub-analysis data at an upcoming oncology congress showing statistical significance in a specific biomarker subset
- Regulatory feedback suggesting openness to a narrower indication based on secondary endpoints
Complete Program Abandonment in NSCLC (15%)
Gilead will entirely write off the lung cancer indication for sacituzumab govitecan, forcing a severe valuation downward revision for their oncology pipeline.
- Gilead issues a formal corporate update removing sacituzumab govitecan from its near-term NSCLC regulatory filing timeline
- Partner Merck drops financial co-funding for the lung cancer combination arm
What to watch
- Full presentation of EVOKE-03/KEYNOTE-D46 secondary endpoint data at the next major oncology medical meeting (next 60 days)
- Gilead's upcoming quarterly earnings call commentary regarding R&D expense allocation for Trodelvy combinations (next 30-90 days)
- ClinicalTrials.gov registry updates showing protocol modifications or suspensions for other EVOKE trials (next 60 days)
Timeline
- — Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC (PR Newswire)
Analysis — what this means
Sectors affected
- Oncology
- Non‑small cell lung cancer therapeutics
Key entities
Sources
- Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC — PR Newswire
Related cases
- Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
- Akeso initiates Phase II trial of a novel TROP2/Nectin-4 bispecific ADC combined with Ivonescimab, advancing its oncology pipeline in NSCLC
- Kelun-Biotech’s Phase III trial shows its antibody-drug conjugate plus pembrolizumab beats chemo‑immunotherapy in PD‑L1‑negative NSCLC, potentially reshaping first‑line lung‑cancer treatment